by Prateek Chopra | June 3, 2026 | Cardiology Conferences | ESH 2026
Clinical Context:
Cardiovascular-kidney-metabolic (CKM) syndrome encompasses overlapping progression of cardiovascular disease, chronic kidney disease, obesity, diabetes, and hypertension, resulting in persistent myocardial injury and increased heart failure risk. Contemporary management focuses on integrated therapies targeting cardio-renal-metabolic pathways to prevent progressive cardiac damage.
Key Pathophysiology & Mechanisms:
- RAAS activation, endothelial dysfunction, inflammation, and myocardial fibrosis drive CKM progression.
- RAAS inhibition with ACE inhibitors, ARBs, and angiotensin receptor–neprilysin inhibitors (ARNI) reduces adverse cardiac remodeling (PARADIGM-HF: sacubitril/valsartan reduced CV death and HF hospitalization vs enalapril).
Emerging Therapeutic Strategies:
- SGLT2 Inhibitors: Enhance natriuresis, restore tubuloglomerular feedback, reduce intraglomerular pressure, and provide broad cardio-renal protection. EMPEROR-Reduced and EMPEROR-Preserved: empagliflozin reduced CV death and HF hospitalization and slowed renal function decline.
- Endothelin Receptor Antagonism + SGLT2i: Potential future approach targeting RAAS and endothelin pathways.
- Finerenone: Non-steroidal MRA; FINEARTS-HF demonstrated reductions in CV death and total HF events in patients with LVEF ≥40%.
- Semaglutide: STEP-HFpEF trials showed improved HF symptoms, exercise capacity, body weight reduction, and reduced inflammatory markers in obesity-related HFpEF.
Clinical Implications:
- Integrated multi-pathway intervention targeting RAAS, mineralocorticoid receptor signaling, metabolic dysfunction, and inflammation represents a major advancement in CKM management.
- Therapies including ARNI, SGLT2 inhibitors, finerenone, and semaglutide provide substantial potential to prevent progressive cardiac damage and improve long-term cardio-renal outcomes in high-risk CKM populations.
Multi-targeted pharmacological strategies in CKM syndrome enhance personalized care, reduce cardiac damage progression, and optimize long-term cardiovascular and renal outcomes.